Technology

Rhythm Pharmaceuticals

$31.11
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.92 (-8.58%) Today
$0.00 (0.00%) As of 11:40 AM UTC after-hours

Why Robinhood?

You can buy or sell RYTM and other stocks, options, and ETFs commission-free!

About RYTM

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA. The listed name for RYTM is Rhythm Pharmaceuticals, Inc. Common Stock.

CEO
David P. Meeker
Employees
70
Headquarters
Boston, Massachusetts
Founded
2010
Market Cap
1.58B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
585.51K
High Today
$34.05
Low Today
$30.35
Open Price
$34.05
Volume
1.01M
52 Week High
$43.26
52 Week Low
$12.99

Collections

RYTM Earnings

-$1.24
-$0.83
-$0.41
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 1, Pre-Market

You May Also Like

JUST
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure